Description: SOA Names Morgan State University to its University-Earned Credit Diversity Extension Program

Description: With a quickly changing set of actuarial tools and practices emerging through artificial intelligence, technology regulations, Actuarial Standards of Practice, and more, it’s important to learn and discuss how to maintain professionalism in actuarial work and in consideration of the SOA Code of Conduct. Come to this session to learn about a variety of emerging topics, discuss case studies, and interact with other attendees to share your perspectives on maintaining a professional approach to valuation topics.By attending the session, you will be able to:· Apply actuarial professionalism concepts.· Identify key ASOPs and Code of Conduct Precepts for actuaries.· Learn about statistical methods and bias.

Description: This session will dive into how artificial intelligence is poised to reshape the actuarial profession. Attendees will learn about the potential impacts of AI on actuarial tasks. The presentation will highlight both the opportunities and challenges that AI presents to actuaries.

Description: America’s healthcare results are lackluster and worsening despite enormous effort and investment over many decades. Spending, affordability, health, coverage, access, quality, and healthcare workforce results are suboptimal or poor. Too many are suffering, and the system is financially unsustainable. We need a new approach, a new way of thinking about healthcare financing and delivery.

Description: Attend this webcast to learn more on how to navigate managing ESG principles in the new normal of a post-COVID world. Enhance your ESG insights in a post-pandemic landscape.

Description: The Society of Actuaries (SOA) Research Institute’s Mortality and Longevity Strategic Research Program Steering Committee established a call for essays series to gather a variety of perspectives on the application of AI to mortality and longevity. The objective of this call for essays, the second in the series, is to create a resource that focuses on the use of AI to potentially extend human longevity and the implications for modeling future survival/mortality.

Description: Court is in session and you are the jury! Follow along as challenging aspects of actuarial professionalism are explored in a court-like setting. Deliberate among your peers based on what you already know from your own experience as well as what you learn in this session, and then deliver your verdict accordingly.

Description: In the time since the original proposal to move healthwriting companies from the blue blank to the orange blank, there have been several incremental updates to the blue blank by the NAIC Blanks Working Group to integrate portions of the orange blank into the blue blank. Meanwhile, the NAIC RBC Working Group has issued their proposal to change the health test for comment and appear to be moving forward with the proposal to revise the health test. This would obligate companies that write predominantly health business onto the orange blank rather than the blue blank, which they have historically used for reporting. Discover background of the revised health test, the incremental updates to the blue blank that have been implemented recently, additional incremental updates proposed for upcoming blue blanks, and the current status of the Health RBC Working Group proposal to revise the health test. Hear observations about companies that have opted to 'take the plunge' and move to the orange blank ahead of the revised health test as well as companies that have opted to remain on the blue blank and incrementally update as new requirements are integrated into the Blue blank. By attending the session, you will be able to: • Understand the context of the initiative to revise the NAIC health test. • Summarize the recent changes to the blue blank implemented by the Blanks Working Group that integrate portions of the orange blank into the blue blank. • Summarize the upcoming proposed changes to the blue blank by the Blanks Working Group that integrate additional portions of the orange blank into the blue blank. • Summarize the current status of the Health RBC Working Group proposal to revise the health test. • Provide industry perspective on companies that have opted to move to the orange blank ahead of the revised health test and companies that have opted to remain on the blue blank until the NAIC requires it.

Description: Address issues in value-based contract accounting from an actuarial perspective. In Medicare and ACA business, what issues does risk adjustment present to value-based contract accounting? In Medicare, what issues do Part D present in value-based contract accounting and what are possible solutions? What are the issues in the use of provider stop loss in value-based contract accounting? Are there issues in the timeliness of claims in value-based contract accounting? Are we giving providers enough information for them to manage their population? How do we deal with deficit accounts? What are the pros and cons of capitation, gainshare, and full risk in value-based accounting?

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.